|
|
|
|
|
|
|
23.02.26 - 20:01
|
Trade Uncertainty Rattles Global Stock Markets | Open Interest 2/23/2026 (Bloomberg)
|
|
|
Get a jump start on the US trading day with Matt Miller and Dani Burger on "Bloomberg Open Interest." Trade uncertainty rattles markets again as President Trump moves forward with sweeping new global tariffs following a Supreme Court decision. We speak to Rep. Jason Smith, the Chairman of the House Ways and Means Committee about what's next. Plus, the CEOs of Mazda North America and Freeport-McMoRan join Bloomberg Open Interest to talk about the impact on their businesses. Novo plunges. Merck splits. Gilead makes a deal. We're tracking a flurry of pharma headlines this morning. And Blue Owl's selloff is deepening fears about liquidity risks inside the $1.8 trillion private credit market. (Source: Bloomberg)...
|
|
|
|
|
|
|
|
|
|
|
23.02.26 - 13:42
|
Gilead Sciences schlägt zu – 68 Prozent Aufschlag (Der Aktionaer)
|
|
|
Die US-amerikanische Biotech-Gesellschaft Gilead Sciences will sich im Bereich der Onkologie verstärken. Mit der geplanten Übernahme von Arcellx erwirbt das Unternehmen die volle Kontrolle über eine neuartige Zelltherapie zur Behandlung des Multiplen Myeloms, einer der häufigsten Tumorerkrankungen von Knochen und Knochenmark....
|
|
|
|
|
|
|
23.02.26 - 13:15
|
Gilead Sciences auf Einkaufstour: Wer folgt als Nächstes? (Sharedeals)
|
|
|
Gilead Sciences lässt seinen Worten Taten folgen: Mit einer ersten Multi-Milliarden-Übernahme im laufenden Jahr stärkt der Pharmakonzern seine Pipeline. Weiterhin ausstehend: eine bedeutende Transaktion im Kernsegment Virologie. Der US-Pharmariese Gilead Sciences baut seine Position im wachstumsstarken Markt für Zelltherapien deutlich aus und übernimmt den Krebsmedikamentenentwickler Arcellx in einem milliardenschweren Deal. Wie beide Unternehmen am Montag […]
The post Gilead Sciences auf Einkaufstour: Wer folgt als Nächstes? first appeared on sharedeals.de....
|
|
|
|
|
23.02.26 - 12:48
|
Gilead Sciences To Acquire Arcellx (AFX)
|
|
|
FOSTER CITY (dpa-AFX) - Gilead Sciences (GILD) has entered into a definitive agreement to acquire Arcellx (ACLX) for $115 per share in cash at closing and one contingent value right of $5 per shar......
|
|
|
|
|
|
|
|
|
|
|
|
|
23.02.26 - 12:06
|
Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel (Business Wire)
|
|
|
– Builds on Successful 2022 Collaboration on Anito-cel, a Potentially Transformative Treatment for Patients with Multiple Myeloma –
– FDA Accepted Anito-cel BLA for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma –
– Provides Gilead with Full Control of Anito-cel, Accelerating Development and Commercialization while Eliminating Profit-Share, Milestones, and Royalties –FOSTER CITY, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--#ACLX--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire Arcellx (Nasdaq: ACLX) for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Arcellx is a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incurable diseases.
Kite, a Gilead company, and Arcellx have an existing collaboration to co-develop and co-com...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
